BRAF-activating mutations have been detected in nearly all craniopharyngiomas of the papillary subtype, with interesting implications for patients with suboptimal tumor control. Here we report that combined treatment with BRAF and MEK inhibitors resulted in major clinical benefit in the case of a patient with a BRAF V600E-mutant papillary craniopharyngioma rapidly progressing after surgery.
Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma / Di Stefano, A. L.; Guyon, D.; Sejean, K.; Feuvret, L.; Villa, C.; Berzero, G.; Desforges Bullet, V.; Halimi, E.; Boulin, A.; Baussart, B.; Gaillard, S.. - In: NEURO-ONCOLOGY ADVANCES. - ISSN 2632-2498. - 2:1(2020). [10.1093/noajnl/vdaa141]
Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
Berzero G.;
2020-01-01
Abstract
BRAF-activating mutations have been detected in nearly all craniopharyngiomas of the papillary subtype, with interesting implications for patients with suboptimal tumor control. Here we report that combined treatment with BRAF and MEK inhibitors resulted in major clinical benefit in the case of a patient with a BRAF V600E-mutant papillary craniopharyngioma rapidly progressing after surgery.| File | Dimensione | Formato | |
|---|---|---|---|
|
vdaa141.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
230.91 kB
Formato
Adobe PDF
|
230.91 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
